Market Overview

UPDATE: JP Morgan Initiates DaVita HealthCare Partners at Overweight on Growth Outlook

Related DVA
Earnings Scheduled For July 31, 2014
DaVita HealthCare Shares Slip Amid Raymond James Downgrade

JP Morgan initiated coverage on DaVita HealthCare Partners (NYSE: DVA) with an Overweight rating and a $125 price target.

JP Morgan said, "By combining the steady growth and cash generation of the company's core dialysis business with the best physician practice management asset in the country, HealthCare Partners (HCP), CEO Kent Thiry has positioned DVA at the forefront of a potentially long-term shift in healthcare delivery and reimbursement heading into reform implementation. The capability of properly incentivized, sophisticated primary care physicians to lower system costs is unquestioned, leaving only the pace and magnitude of opportunity to be decided going forward, with DVA perhaps best positioned of all to benefit."

DaVita HealthCare Partners closed at $110.87 on Wednesday.

Posted-In: JP MorganAnalyst Color Initiation Intraday Update Analyst Ratings

 

Most Popular

Related Articles (DVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters